title: Influence of layer-by-layer (LbL) assembled CaCO(3)-carriers on macrophage signaling cascades.
abstract: Numerous drawbacks in the current medical treatment of chronic inflammations still require the design of sensitive and gentle methods without side effects. Layer-by-layer (LbL) coated microcarriers loaded with a cocktail of anti-inflammatory substances are supposed to be a new challenge for the medical treatment of immunoreactive cells such as macrophages and polymorphonuclear leukocytes (PMN). Nevertheless, microcarrier application requires biocompatibility of the system itself. Therefore, the aim of this study was to investigate microcarrier CaCO(3) systems LbL coated with biopolymers and a lipid bilayer, respectively, regarding the maintenance of the release of pro-inflammatory cytokines as TNFα and IL1β at normal levels. Only marginal increases after microcarrier interaction were allowed. The required microcarrier optimization results in the maximum use of a carrier/cell ratio of 1:1 for biopolymer-coated carriers and a carrier/cell ratio up to 5:1 for lipid-bilayer-coated carriers during the coincubation with macrophage-like cells. Low formation of reactive oxygen species (ROS) could not be maintained by either reduced carrier/cell ratios or by a surface lipid bilayer.
authors.affiliation: Translational Centre for Regenerative Medicine (TRM), Universität Leipzig, Germany. jacqueline.lessig@medizin.uni-leipzig.de
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Lessig
authors.forename: Björn
authors.initials: B
authors.lastname: Neu
authors.forename: Uta
authors.initials: U
authors.lastname: Reibetanz
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology*; D002119:Calcium Carbonate / Q000737:chemistry / Q000494:pharmacology*; D002908:Chronic Disease; D020099:Coated Materials, Biocompatible / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D053583:Interleukin-1beta / Q000096:biosynthesis; D008051:Lipid Bilayers / Q000737:chemistry / Q000494:pharmacology*; D008264:Macrophages / Q000166:cytology / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D020298:U937 Cells
chemical_list: D000893:Anti-Inflammatory Agents; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D008051:Lipid Bilayers; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D002119:Calcium Carbonate